title: The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted.
abstract: Although US Food and Drug Administration (FDA)-approved Biopharmaceutics Classification System (BCS) class 1 drugs are designated as high-permeability drugs, in fact, the criterion utilized is high extent of absorption. This ambiguity should be eliminated, and the FDA criterion should explicitly be stated as > or =90% absorption based on absolute bioavailability or mass balance. Maintaining confidentiality regarding the drugs for which the FDA has approved BCS waivers of in vivo bioequivalence studies is not good public policy and should be reversed.
authors.affiliation: Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California, San Francisco, San Francisco, California, USA. leslie.benet@ucsf.edu
authors.forename: L Z
authors.initials: LZ
authors.lastname: Benet
authors.forename: C A
authors.initials: CA
authors.lastname: Larregieu
mesh_terms: D000818:Animals; D001682:Biological Availability; D001702:Biopharmaceutics / Q000145:classification*; D017277:Drug Approval; D006801:Humans; D007408:Intestinal Absorption; D010539:Permeability; D004364:Pharmaceutical Preparations / Q000145:classification* / Q000378:metabolism; D012995:Solubility; D013810:Therapeutic Equivalency; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D004364:Pharmaceutical Preparations